EPO and early-onset autosomal dominant Alzheimer disease: For example, systemic administration of EPO has been found to reduce neural tissue damage in mouse models of ischemia, traumatic brain injury, autoimmune encephalitis, seizures, Alzheimer’s disease, and amyotrophic lateral sclerosis (227, 236, 238–240).